CD19 and acute lymphoblastic leukemia: CD-19-directed therapies for relapsed and refractory NHL and ALL include axicabtagene autoleucel (axi-cel), tisagenlecleucel (tisacel), brexucabtagene autoleucel (brexu-cel) and lisocabtagene maraleucel (liso-cel).1–7